TD Cowen downgraded Medpace (MEDP) to Hold from Buy with a price target of $328, down from $370. The firm cites the challenging biotech funding and uncertain regulatory environment for the downgrade. This may lead to slower trial activity and more restricted biotech investment, the analyst tells investors in a research note. TD says that while Medpace will be able to see revenue growth starting in 2026 through market share gains, the macro environment offers little upside in 2025 and an uncertain 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: